The effect of initiation of renin-angiotensin system inhibitors on haemoglobin: A national cohort study

Aims To determine whether initiation of treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARBs) is associated with a subsequent reduction in haemoglobin in the general population. Methods We undertook a national cohort study over a 13-year period (2004-2016), using routine primary healthcare data from the UK Clinical Practice Research Datalink. We compared ACEI/ARB initiation with calcium channel blocker (CCB) initiation, to minimise confounding by indication. We included all first ACEI/ARB or CCB prescriptions in adults with at least 1 haemoglobin result in the 12 months before and 6 months after drug initiation. Our primary outcome was a >= 1 g/dL haemoglobin reduction in the 6 months after drug initiation. Results We examined 146 610 drug initiation events in 136 655 patients. Haemoglobin fell by >= 1 g/dL after drug initiation in 19.5% (16 936/86 652) of ACEI/ARB initiators and 15.9% (9521/59 958) of CCB initiators. The adjusted odds ratio of a >= 1 g/dL haemoglobin reduction in ACEI/ARB initiatorsvsCCB initiators was 1.15 (95% confidence interval 1.12-1.19). Conclusion ACEI/ARBs are associated with a modest increase in the risk of a haemoglobin reduction. For every 100 patients in our study that initiated a CCB, 16 experienced a >= 1 g/dL haemoglobin decline. If the effect is causal, 3 additional patients would have experienced this outcome if they had received an ACEI/ARB. This may have implications for drug choice and monitoring for many patients in primary care. Further research could identify patients at higher risk of this outcome, who may benefit from closer monitoring.

Automated summary

Initiating treatment with ACEI/ARBs may be associated with a modest increase in the risk of haemoglobin reduction. For every 100 patients starting on a CCB, 16 experienced a >= 1 g/dL haemoglobin decline, with 3 additional patients experiencing this outcome if they had received an ACEI/ARB. This may have implications for drug choice and monitoring in primary care.